Amgen Hedges On Sandoz's High Court Biosimilar Petition

By Jeff Overley (March 22, 2016, 5:41 PM EDT) -- Amgen on Tuesday said the U.S. Supreme Court should reject Sandoz's bid to revisit one part of a landmark Federal Circuit ruling on the obligations of biosimilar makers, but added that another part of the ruling should also be revisited if the justices do decide to weigh in....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!